Ironwood Pharmaceuticals, Inc. (IRWD) News
Follow Ironwood Pharmaceuticals, Inc. (IRWD) news in one place: company catalysts, earnings, analyst actions and wider market developments. Review 10 public stories across 6 publication days to understand how the story developed. Public news appears after a 15-minute delay; LiveCast subscribers can follow new headlines and hear important updates without this additional delay.
M
Windward Bio Raises $175 Million in US IPO
Novo Holdings-backed Windward Bio raised $175 million in a U.S. IPO.
MNA | Nov 13, 2026, 12:00 AM UTC
L
Ironwood Pharmaceuticals 3Q 2026: Revenue $133.04M, EPS $0.36 — 10-Q Summary
Ironwood Pharmaceuticals’ third-quarter revenue and net income rose year over year, with revenue growth driven primarily by increased U.S. LINZESS prescription demand, partly offset by net price. Earnings also benefited
EARNINGS | Nov 05, 2026, 09:13 PM UTC
M
Ironwood Pharmaceuticals Raises 2026 Revenue View to $485M-$510M
EARNINGS | Nov 05, 2026, 12:55 PM UTC
M
Ironwood Raises Full-Year 2026 Guidance After Third-Quarter Results
Ironwood said U.S. LINZESS net sales year to date surpassed total 2025 sales, citing sales growth as it raised guidance for the second consecutive quarter.
EQUITY | Nov 05, 2026, 12:05 PM UTC
L
Ironwood Pharmaceuticals Reports Third-Quarter Adjusted EPS
EARNINGS | Nov 05, 2026, 12:05 PM UTC
L
Ironwood Pharmaceuticals Reports Third-Quarter Net Income of $59.8 Million
EARNINGS | Nov 05, 2026, 12:05 PM UTC
H
Ironwood Pharmaceuticals Reports Q2 2026 Results: Full Earnings Call Transcript
Ironwood Pharmaceuticals (NASDAQ: IRWD ) reported second-quarter financial results on Thursday. The transcript from the company's second-quarter earnings call has been provided below. This content is powered APIs. For co
LIVE | Oct 05, 2026, 01:08 PM UTC
L
Ironwood Pharmaceuticals to participate in Wells Fargo healthcare conference fireside chat
Ironwood Pharmaceuticals will participate in a fireside chat at the Wells Fargo 21st Annual Healthcare Conference on Thursday, September 10 at 10:15 a.m. ET. A live webcast will be available via Investors & Media.
EQUITY | Sep 03, 2026, 08:05 PM UTC
L
Ironwood Pharmaceuticals Raises FY2026 Sales Guidance from $450.000M-$475.000M to $460.000M-$485.000M vs $460.118M Est
Ironwood Pharmaceuticals (NASDAQ: IRWD ) raises FY2026 sales outlook from $450.000 million-$475.000 million to $460.000 million-$485.000 million vs $460.118 million estimate.
EARNINGS | Aug 06, 2026, 11:09 AM UTC
L
IRWD Ironwood appoints Dr. Jeffrey silber chief Medical officer and head of research and drug development; stars-2 trial initiated in June a
IRWD Ironwood appoints Dr. Jeffrey silber chief Medical officer and head of research and drug development; stars-2 trial initiated in June and is now actively recruiting patients Ironwood Pharmaceuticals - initiates phas
EQUITY | Jul 14, 2026, 11:31 AM UTC